{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:47:02Z","timestamp":1791827222017,"version":"4.3.4"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Drug Discov."],"DOI":"10.1038\/s44386-026-00080-3","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:06:52Z","timestamp":1791824812000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Proportionate evidence in biosimilar development: when a comparative efficacy study can still change the regulatory conclusion"],"prefix":"10.1038","volume":"3","author":[{"given":"Sarfaraz K.","family":"Niazi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,12]]},"reference":[{"key":"80_CR1","unstructured":"European Medicines Agency. Guideline on similar biological medicinal products. CHMP\/437\/04 Rev. 1. London: European Medicines Agency; 2014 (effective 2015) https:\/\/www.ema.europa.eu\/en\/similar-biological-medicinal-products-scientific-guideline (accessed on 5 August 2026)."},{"key":"80_CR2","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1146\/annurev-med-041715-033438","volume":"68","author":"LA Christl","year":"2017","unstructured":"Christl, L. A., Woodcock, J. & Kozlowski, S. Biosimilars: The US regulatory framework. Annu. Rev. Med. 68, 243\u2013254 https:\/\/doi.org\/10.1146\/annurev-med-041715-033438 (2017).","journal-title":"Annu. Rev. Med."},{"key":"80_CR3","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/nrd374","volume":"11","author":"SA Berkowitz","year":"2012","unstructured":"Berkowitz, S. A., Engen, J. R., Mazzeo, J. R. & Jones, G. B. Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars. Nat. Rev. Drug Discov. 11, 527\u2013540 https:\/\/doi.org\/10.1038\/nrd374 (2012).","journal-title":"Nat. Rev. Drug Discov."},{"key":"80_CR4","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1021\/ac3032355","volume":"85","author":"A Beck","year":"2013","unstructured":"Beck, A., Wagner-Rousset, E., Ayoub, D., Van Dorsselaer, A. & Sanglier-Cianferani, S. Characterization of therapeutic antibodies and related products. Anal. Chem. 85, 715\u2013736 https:\/\/doi.org\/10.1021\/ac3032355 (2013).","journal-title":"Anal. Chem."},{"key":"80_CR5","unstructured":"World Health Organization. Guidelines on evaluation of biosimilars. WHO Technical Report Series 1043, Annex 3. Geneva: World Health Organization; 2022 https:\/\/www.who.int\/publications\/m\/item\/guidelines-on-evaluation-of-biosimilars (accessed 5 August 2026)."},{"key":"80_CR6","unstructured":"Medicines and Healthcare products Regulatory Agency. Guidance on the licensing of biosimilar products. London: MHRA; substantive revision 20 December 2024, page updated 27 February 2025 https:\/\/www.gov.uk\/government\/publications\/guidance-on-the-licensing-of-biosimilar-products\/guidance-on-the-licensing-of-biosimilar-products (accessed 5 August 2026)."},{"key":"80_CR7","unstructured":"European Medicines Agency. Reflection paper on a tailored clinical approach in biosimilar development. EMA\/CHMP\/BMWP\/60916\/2025. Amsterdam: European Medicines Agency; adopted 16 March 2026 https:\/\/www.ema.europa.eu\/en\/documents\/other\/reflection-paper-tailored-clinical-approach-biosimilar-development_en.pdf (accessed 5 August 2026)."},{"key":"80_CR8","unstructured":"United States Food and Drug Administration. Development of Therapeutic Protein Biosimilars: Comparative Analytical Assessment and Other Quality-Related Considerations. Guidance for Industry (final). Docket No. FDA-2019-D-2102. Silver Spring, MD: FDA; issued 9 September 2025 https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/development-therapeutic-protein-biosimilars-comparative-analytical-assessment-and-other (accessed 5 August 2026)."},{"key":"80_CR9","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1002\/cpt.2785","volume":"113","author":"E Guillen","year":"2023","unstructured":"Guillen, E., Ekman, N., Barry, S., Weise, M. & Wolff-Holz, E. A. data-driven approach to support tailored clinical programs for biosimilar monoclonal antibodies. Clin. Pharm. Ther. 113, 108\u2013123 https:\/\/doi.org\/10.1002\/cpt.2785 (2023).","journal-title":"Clin. Pharm. Ther."},{"key":"80_CR10","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s40259-023-00631-4","volume":"37","author":"N Kirsch-Stefan","year":"2023","unstructured":"Kirsch-Stefan, N. et al. E. Do the outcomes of clinical efficacy trials matter in regulatory decision making for biosimilars? BioDrugs 37, 855\u2013871 https:\/\/doi.org\/10.1007\/s40259-023-00631-4 (2023).","journal-title":"BioDrugs"},{"key":"80_CR11","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s40265-025-02168-y","volume":"85","author":"E Guillen","year":"2025","unstructured":"Guillen, E., Wolff-Holz, E. & Weise, M. The tailored biosimilar approach: expectations and requirements. Drugs 85, 601\u2013608 https:\/\/doi.org\/10.1007\/s40265-025-02168-y (2025).","journal-title":"Drugs"},{"key":"80_CR12","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s40259-020-00422-1","volume":"34","author":"M Schiestl","year":"2020","unstructured":"Schiestl, M. et al. The path towards a tailored clinical biosimilar development. BioDrugs 34, 297\u2013306 https:\/\/doi.org\/10.1007\/s40259-020-00422-1 (2020).","journal-title":"BioDrugs"},{"key":"80_CR13","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1016\/j.drudis.2020.09.006","volume":"25","author":"MC Bielsky","year":"2020","unstructured":"Bielsky, M. C. et al. Streamlined approval of biosimilars: moving on from the confirmatory efficacy trial. Drug Discov. Today 25, 1910\u20131918 https:\/\/doi.org\/10.1016\/j.drudis.2020.09.006 (2020).","journal-title":"Drug Discov. Today"},{"key":"80_CR14","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1080\/14712598.2024.2314612","volume":"24","author":"C Nick","year":"2024","unstructured":"Nick, C. Streamlining biosimilar development based on 20 years of experience. Expert Opin. Biol. Ther. 24, 143\u2013149 https:\/\/doi.org\/10.1080\/14712598.2024.2314612 (2024).","journal-title":"Expert Opin. Biol. Ther."},{"key":"80_CR15","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.2147\/DDDT.S378813","volume":"16","author":"SK Niazi","year":"2022","unstructured":"Niazi, S. K. Scientific rationale for waiving clinical efficacy testing of biosimilars. Drug Des. Devel Ther. 16, 2803\u20132815 https:\/\/doi.org\/10.2147\/DDDT.S378813 (2022).","journal-title":"Drug Des. Devel Ther."},{"key":"80_CR16","doi-asserted-by":"publisher","first-page":"779","DOI":"10.3390\/ph18060779","volume":"18","author":"SK Niazi","year":"2025","unstructured":"Niazi, S. K. Scientific justification and policy recommendations to the United States Food and Drug Administration for waiving comparative efficacy studies. Pharmaceuticals 18, 779 https:\/\/doi.org\/10.3390\/ph18060779 (2025).","journal-title":"Pharmaceuticals"},{"key":"80_CR17","unstructured":"United States Food and Drug Administration. Purple Book: database of licensed biological products, Advanced Search export reflecting licensures through 31 July 2026. Silver Spring, MD: FDA; retrieved 6 August 2026 https:\/\/purplebooksearch.fda.gov\/ [Frozen copy, filter definitions, and checksum provided as Supplementary Material S1.] (accessed on 5 August 2026)."},{"key":"80_CR18","unstructured":"European Medicines Agency. Medicines: human medicines table export, biosimilar and medicine status fields. Amsterdam: European Medicines Agency; generated and downloaded 6 August 2026. Frozen copy (medicines-output-medicines-report_en.xlsx), filter definitions, and SHA-256 checksum provided as Supplementary Material S1. (accessed on 5 August 2026)."},{"key":"80_CR19","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1001\/jamainternmed.2020.3997","volume":"181","author":"TJ Moore","year":"2021","unstructured":"Moore, T. J., Mouslim, M. C., Blunt, J. L., Alexander, G. C. & Shermock, K. M. Assessment of availability, clinical testing, and US Food and drug administration review of biosimilar biologic products. JAMA Intern Med. 181, 52\u201360 https:\/\/doi.org\/10.1001\/jamainternmed.2020.3997 (2021).","journal-title":"JAMA Intern Med."},{"key":"80_CR20","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/nbt.1839","volume":"29","author":"M Schiestl","year":"2011","unstructured":"Schiestl, M. et al. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat. Biotechnol. 29, 310\u2013312 https:\/\/doi.org\/10.1038\/nbt.1839 (2011).","journal-title":"Nat. Biotechnol."},{"key":"80_CR21","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1208\/s12248-026-01206-1","volume":"28","author":"AS Rathore","year":"2026","unstructured":"Rathore, A. S. et al. Best practices for performing analytical and functional biosimilarity assessment of recombinant monoclonal antibody biosimilars. AAPS J. 28, 62 https:\/\/doi.org\/10.1208\/s12248-026-01206-1 (2026).","journal-title":"AAPS J."},{"key":"80_CR22","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s40259-026-00786-w","volume":"40","author":"R Aithal","year":"2026","unstructured":"Aithal, R., Majedi, O. M., McCarthy, D., Atouf, F. & Peckham, N. Review of quality attributes and analytical methods used for comparative analytical assessment of monoclonal antibodies as part of successful biosimilar approvals in the United States and European Union. BioDrugs 40, 713\u2013732 https:\/\/doi.org\/10.1007\/s40259-026-00786-w (2026).","journal-title":"BioDrugs"},{"key":"80_CR23","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1080\/10543406.2016.1272606","volume":"27","author":"Y Tsong","year":"2017","unstructured":"Tsong, Y., Dong, X. & Shen, M. Development of statistical methods for analytical similarity assessment. J. Biopharm. Stat. 27, 197\u2013205 https:\/\/doi.org\/10.1080\/10543406.2016.1272606 (2017).","journal-title":"J. Biopharm. Stat."},{"key":"80_CR24","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1208\/s12248-016-9968-0","volume":"19","author":"RK Burdick","year":"2017","unstructured":"Burdick, R. K. et al. Statistical approaches to assess biosimilarity from analytical data. AAPS J. 19, 4\u201314 https:\/\/doi.org\/10.1208\/s12248-016-9968-0 (2017).","journal-title":"AAPS J."},{"key":"80_CR25","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s40259-014-0088-z","volume":"28","author":"S Ramanan","year":"2014","unstructured":"Ramanan, S. & Grampp, G. Drift, evolution, and divergence in biologics and biosimilars manufacturing. BioDrugs 28, 363\u2013372 https:\/\/doi.org\/10.1007\/s40259-014-0088-z (2014).","journal-title":"BioDrugs"},{"key":"80_CR26","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1080\/14712598.2018.1421169","volume":"18","author":"WC Lamanna","year":"2018","unstructured":"Lamanna, W. C. et al. Maintaining consistent quality and clinical performance of biopharmaceuticals. Expert Opin. Biol. Ther. 18, 369\u2013379 https:\/\/doi.org\/10.1080\/14712598.2018.1421169 (2018).","journal-title":"Expert Opin. Biol. Ther."},{"key":"80_CR27","unstructured":"United States Food and Drug Administration. Process validation: general principles and practices. Guidance for Industry. Silver Spring, MD: FDA; January 2011. chrome-extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/ https:\/\/www.fda.gov\/files\/drugs\/published\/Process-Validation--General-Principles-and-Practices.pdf. (accessed on 5 August 2026)."},{"key":"80_CR28","unstructured":"International Council for Harmonisation. ICH Q5E: comparability of biotechnological and biological products subject to changes in their manufacturing process. Geneva: ICH; 2004 https:\/\/www.ema.europa.eu\/en\/ich-q5e-biotechnological-biological-products-subject-changes-their-manufacturing-process-comparability-biotechnological-biological-products-scientific-guideline (accessed on 5 August 2026)."},{"key":"80_CR29","unstructured":"Commission Regulation (EC) No 1234\/2008 of 24 November 2008 concerning the examination of variations to the terms of marketing authorisations for medicinal products for human use and veterinary medicinal products, as amended. Official Journal of the European Union L 334, 12 December 2008 https:\/\/eur-lex.europa.eu\/eli\/reg\/2008\/1234\/oj\/eng (accessed on 5 August 2026)."},{"key":"80_CR30","unstructured":"United States Food and Drug Administration. Cross discipline team leader review, BLA 761024, ABP 501 (adalimumab-atto), Amjevita. Silver Spring, MD: FDA; 2016. Available from the FDA Drugs@FDA database, BLA 761024 https:\/\/www.drugs.com\/history\/amjevita.html (accessed 5 August 2026)."},{"key":"80_CR31","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1136\/annrheumdis-2015-207764","volume":"76","author":"JY Choe","year":"2017","unstructured":"Choe, J. Y. et al. A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy. Ann. Rheum. Dis. 76, 58\u201364 https:\/\/doi.org\/10.1136\/annrheumdis-2015-207764 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"80_CR32","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13075-020-2142-1","volume":"22","author":"MC Genovese","year":"2020","unstructured":"Genovese, M. C. et al. Comparative clinical efficacy and safety of the proposed biosimilar ABP 710 with infliximab reference product in patients with rheumatoid arthritis. Arthritis Res Ther. 22, 60 https:\/\/doi.org\/10.1186\/s13075-020-2142-1 (2020).","journal-title":"Arthritis Res Ther."},{"key":"80_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2026.1779934","volume":"13","author":"SK Niazi","year":"2026","unstructured":"Niazi, S. K. Non-signaling protein therapeutics: a mechanism based regulatory framework to modernize biosimilar development and global harmonization. Front Med. 13, 1779934 https:\/\/doi.org\/10.3389\/fmed.2026.1779934 (2026).","journal-title":"Front Med."},{"key":"80_CR34","unstructured":"United States Food and Drug Administration. Clinical pharmacology data to support a demonstration of biosimilarity to a reference product. Guidance for Industry. Silver Spring, MD: FDA; December 2016 https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/clinical-pharmacology-data-support-demonstration-biosimilarity-reference-product (accessed on 5 August 2026)."},{"key":"80_CR35","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1002\/cncr.22402","volume":"109","author":"RA Beckman","year":"2007","unstructured":"Beckman, R. A., Weiner, L. M. & Davis, H. M. Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors. Cancer 109, 170\u2013179 https:\/\/doi.org\/10.1002\/cncr.22402 (2007).","journal-title":"Cancer"},{"key":"80_CR36","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/j.addr.2008.04.012","volume":"60","author":"GM Thurber","year":"2008","unstructured":"Thurber, G. M., Schmidt, M. M. & Wittrup, K. D. Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv. Drug Deliv. Rev. 60, 1421\u20131434 https:\/\/doi.org\/10.1016\/j.addr.2008.04.012 (2008).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"80_CR37","doi-asserted-by":"publisher","first-page":"297","DOI":"10.4161\/mabs.23684","volume":"5","author":"DK Shah","year":"2013","unstructured":"Shah, D. K. & Betts, A. M. Antibody biodistribution coefficients: inferring tissue concentrations of monoclonal antibodies based on the plasma concentrations in several preclinical species and human. mAbs 5, 297\u2013305 https:\/\/doi.org\/10.4161\/mabs.23684 (2013).","journal-title":"mAbs"},{"key":"80_CR38","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/cpt.2761","volume":"113","author":"DG Strauss","year":"2023","unstructured":"Strauss, D. G., Wang, Y. M., Florian, J. & Zineh, I. Pharmacodynamic biomarkers: evidentiary considerations for biosimilar development and approval. Clin. Pharm. Ther. 113, 55\u201361 https:\/\/doi.org\/10.1002\/cpt.2761 (2023).","journal-title":"Clin. Pharm. Ther."},{"key":"80_CR39","unstructured":"United States Food and Drug Administration. New and revised draft questions and answers on biosimilar development and the BPCI Act, Revision 4. Draft Guidance for Industry. Silver Spring, MD: FDA; March 2026 https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/new-and-revised-draft-qas-biosimilar-development-and-bpci-act-revision-4 (accessed on 5 August 2026)."},{"key":"80_CR40","unstructured":"United States Food and Drug Administration. Immunogenicity testing of therapeutic protein products: developing and validating assays for anti-drug antibody detection. Guidance for Industry. Silver Spring, MD: FDA; February 2019 https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/immunogenicity-testing-therapeutic-protein-products-developing-and-validating-assays-anti-drug (accessed on 5 August 2026)."},{"key":"80_CR41","unstructured":"European Medicines Agency. Guideline on immunogenicity assessment of therapeutic proteins. EMEA\/CHMP\/BMWP\/14327\/2006 Rev. 1. London: European Medicines Agency; 2017 https:\/\/www.ema.europa.eu\/en\/immunogenicity-assessment-biotechnology-derived-therapeutic-proteins-scientific-guideline (accessed on 5 August 2026)."},{"key":"80_CR42","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1056\/NEJMoa040528","volume":"351","author":"CL Bennett","year":"2004","unstructured":"Bennett, C. L. et al. Pure red-cell aplasia and epoetin therapy. N. Engl. J. Med. 351, 1403\u20131408 https:\/\/doi.org\/10.1056\/NEJMoa040528 (2004).","journal-title":"N. Engl. J. Med."},{"key":"80_CR43","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1111\/j.1523-1755.2005.00340.x","volume":"67","author":"K Boven","year":"2005","unstructured":"Boven, K. et al. The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. Kidney Int 67, 2346\u20132353 https:\/\/doi.org\/10.1111\/j.1523-1755.2005.00340.x (2005).","journal-title":"Kidney Int"},{"key":"80_CR44","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/jama.2024.21972","volume":"333","author":"World Medical Association","year":"2025","unstructured":"World Medical Association World Medical Association Declaration of Helsinki: ethical principles for medical research involving human participants. JAMA 333, 71\u201374 https:\/\/doi.org\/10.1001\/jama.2024.21972 (2025).","journal-title":"JAMA"},{"key":"80_CR45","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1001\/jama.283.20.2701","volume":"283","author":"EJ Emanuel","year":"2000","unstructured":"Emanuel, E. J., Wendler, D. & Grady, C. What makes clinical research ethical? JAMA 283, 2701\u20132711 https:\/\/doi.org\/10.1001\/jama.283.20.2701 (2000).","journal-title":"JAMA"},{"key":"80_CR46","unstructured":"United States Food and Drug Administration. FDA moves to accelerate biosimilar development and lower drug costs. Press announcement. Silver Spring, MD: FDA; 29 October 2025 https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-moves-accelerate-biosimilar-development-and-lower-drug-costs (accessed 5 August 2026)."},{"key":"80_CR47","doi-asserted-by":"publisher","first-page":"581013","DOI":"10.2147\/BTT.S581013","volume":"20","author":"R Ranbhor","year":"2026","unstructured":"Ranbhor, R. & Kulkarni, P. Net present value impact of FDA phase 3 waivers on monoclonal antibody biosimilar development. Biologics 20, 581013 https:\/\/doi.org\/10.2147\/BTT.S581013 (2026).","journal-title":"Biologics"},{"key":"80_CR48","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.2165\/00019053-200624110-00003","volume":"24","author":"K Claxton","year":"2006","unstructured":"Claxton, K. & Sculpher, M. Using value of information analysis to prioritise health research: some lessons from recent UK experience. Pharmacoeconomics 24, 1055\u20131068 https:\/\/doi.org\/10.2165\/00019053-200624110-00003 (2006).","journal-title":"Pharmacoeconomics"},{"key":"80_CR49","unstructured":"United States Food and Drug Administration. Use of Bayesian methodology in clinical trials of drug and biological products. Draft Guidance for Industry. Silver Spring, MD: FDA; January 2026 https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/use-bayesian-methodology-clinical-trials-drug-and-biological-products (accessed on 5 August 2026)."},{"key":"80_CR50","unstructured":"International Council for Harmonisation. ICH M15: general principles for model informed drug development. Step 4 Guideline. Geneva: ICH; 29 January 2026 https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/m15-general-principles-model-informed-drug-development (accessed on 5 August 2026)."},{"key":"80_CR51","unstructured":"Public Health Service Act, section 351(k), 42 USC 262(k), as amended (current consolidated text) https:\/\/www.regulations.gov\/document\/FDA-2012-N-0129-0006. https:\/\/uscode.house.gov\/view.xhtml?req=(title:42%20section:262%20edition:prelim) (accessed on 5 August 2026)."},{"key":"80_CR52","unstructured":"Directive 2001\/83\/EC of the European Parliament and of the Council on the Community code relating to medicinal products for human use, Article 10(4) and Annex I, Part II, as amended https:\/\/www.wipo.int\/wipolex\/en\/legislation\/details\/13061 (accessed on 5 August 2026)."},{"key":"80_CR53","unstructured":"United States Food and Drug Administration. Scientific Considerations in Demonstrating Biosimilarity to a Reference Product: Updated Recommendations for Assessing the Need for Comparative Efficacy Studies. Draft Guidance for Industry, not for implementation. Docket No. FDA-2011-D-0605. Silver Spring, MD: FDA; issued 29 October 2025 https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/scientific-considerations-demonstrating-biosimilarity-reference-product-updated-recommendations (accessed 5 August 2026)."},{"key":"80_CR54","unstructured":"United States Food and Drug Administration. FDA takes further steps to streamline biosimilar development and make medicines more affordable. Silver Spring, MD: FDA; 9 March 2026 https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-takes-further-steps-streamline-biosimilar-development-and-make-medicines-more-affordable (accessed on 5 August 2026)."},{"key":"80_CR55","unstructured":"United States Food and Drug Administration. Questions and answers on biosimilar development and the BPCI Act. Guidance for Industry. Silver Spring, MD: FDA; March 2026 https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/questions-and-answers-biosimilar-development-and-bpci-act (accessed on 5 August 2026)."},{"key":"80_CR56","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/j.jaci.2026.02.041","volume":"157","author":"S Khan","year":"2026","unstructured":"Khan, S. et al. Food and Drug Administration regulation of biosimilar products: improving affordability of biologics for patients with asthma and allergic diseases. J. Allergy Clin. Immunol. 157, 1009\u20131017 https:\/\/doi.org\/10.1016\/j.jaci.2026.02.041 (2026).","journal-title":"J. Allergy Clin. Immunol."},{"key":"80_CR57","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1001\/jama.2026.3088","volume":"335","author":"MA Makary","year":"2026","unstructured":"Makary, M. A., Yim, S., Unlu, M. & Ricci, M. S. FDA regulatory reforms to unlock competition and lower drug costs: breaking the biosimilar bottleneck. JAMA 335, 1473\u20131474 https:\/\/doi.org\/10.1001\/jama.2026.3088 (2026).","journal-title":"JAMA"},{"key":"80_CR58","unstructured":"European Medicines Agency. Concept paper on revision of: Guideline on similar biological medicinal products, CHMP\/437\/04 Rev.1. EMA\/CHMP\/BMWP\/153523\/2026. Amsterdam: European Medicines Agency; 22 July 2026 https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/concept-paper-revision-guideline-similar-biological-medicinal-products-chmp-437-04-rev1_en.pdf (accessed on 5 August 2026)."},{"key":"80_CR59","unstructured":"International Council for Harmonisation. M18 Framework for Determining the Utility of Comparative Efficacy Studies in Biosimilar Development Programs. Final Concept Paper. Geneva: ICH; 19 November 2025 https:\/\/database.ich.org\/sites\/default\/files\/ICH_M18_Final_Concept_Paper_MCEndorsed_2025_1119.pdf (accessed on 5 August 2026)."},{"key":"80_CR60","unstructured":"International Council for Harmonisation. ICH Association 2026 annual work plan. Geneva: ICH; 2026 https:\/\/admin.ich.org\/sites\/default\/files\/inline-files\/ICHAssociation_WorkPlan_2026_Approved_2025_1118.pdf (accessed on 5 August 2026)."},{"key":"80_CR61","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1080\/14712598.2026.2689744","volume":"26","author":"MS Khan","year":"2026","unstructured":"Khan, M. S., Khan, S. M., Saini, A. K. & Kollipara, S. Comparative overview of biosimilar regulatory frameworks and international harmonization trends. Expert Opin. Biol. Ther. 26, 587\u2013604 https:\/\/doi.org\/10.1080\/14712598.2026.2689744 (2026).","journal-title":"Expert Opin. Biol. Ther."},{"key":"80_CR62","doi-asserted-by":"publisher","first-page":"e261642","DOI":"10.1001\/jamahealthforum.2026.1642","volume":"7","author":"JH Watanabe","year":"2026","unstructured":"Watanabe, J. H., Strand, M. W., Walvekar, M. & Alfonso-Cristancho, R. Regulatory definitions and classification of biosimilar medications across the six regions of the World Health Organization: a scoping review. JAMA Health Forum 7, e261642 https:\/\/doi.org\/10.1001\/jamahealthforum.2026.1642 (2026). (see correction, reference 63).","journal-title":"JAMA Health Forum"},{"key":"80_CR63","doi-asserted-by":"publisher","unstructured":"Errors in citations and Tables 1 and 4. JAMA Health Forum. 2026;7(7):e262551 https:\/\/doi.org\/10.1001\/jamahealthforum.2026.2551 (accessed on 5 August 2026).","DOI":"10.1001\/jamahealthforum.2026.2551"},{"key":"80_CR64","unstructured":"European Medicines Agency and Heads of Medicines Agencies. Statement on the scientific rationale supporting interchangeability of biosimilar medicines in the European Union. Amsterdam: European Medicines Agency; 2022 https:\/\/www.ema.europa.eu\/en\/documents\/public-statement\/statement-scientific-rationale-supporting-interchangeability-biosimilar-medicines-eu_en.pdf (accessed on 5 August 2026)."},{"key":"80_CR65","unstructured":"United States Food and Drug Administration. Considerations in demonstrating interchangeability with a reference product: update. Draft Guidance for Industry. Silver Spring, MD: FDA; June 2024 https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/considerations-demonstrating-interchangeability-reference-product-update (accessed on 5 August 2026)."},{"key":"80_CR66","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.3389\/fphar.2019.01372","volume":"10","author":"L Colloca","year":"2019","unstructured":"Colloca, L., Panaccione, R. & Murphy, T. K. The clinical implications of nocebo effects for biosimilar therapy. Front Pharm. 10, 1372 https:\/\/doi.org\/10.3389\/fphar.2019.01372 (2019).","journal-title":"Front Pharm."},{"key":"80_CR67","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41584-018-0110-9","volume":"14","author":"E Kravvariti","year":"2018","unstructured":"Kravvariti, E., Kitas, G. D., Mitsikostas, D. D. & Sfikakis, P. P. Nocebos in rheumatology: emerging concepts and their implications for clinical practice. Nat. Rev. Rheumatol. 14, 727\u2013740 https:\/\/doi.org\/10.1038\/s41584-018-0110-9 (2018).","journal-title":"Nat. Rev. Rheumatol."},{"key":"80_CR68","unstructured":"European Medicines Agency. Guideline on process validation for the manufacture of biotechnology-derived active substances and data to be provided in the regulatory submission. EMA\/CHMP\/BWP\/187338\/2014. London: European Medicines Agency; 2016 https:\/\/www.ema.europa.eu\/en\/process-validation-manufacture-biotechnology-derived-active-substances-data-be-provided-regulatory-submission-scientific-guideline (accessed on 5 August 2026)."},{"key":"80_CR69","unstructured":"International Council for Harmonisation. ICH Q13: continuous manufacturing of drug substances and drug products. Step 4 Guideline. Geneva: ICH; adopted 16 November 2022 https:\/\/database.ich.org\/sites\/default\/files\/ICH_Q13_Step4_Guideline_2022_1116.pdf (accessed on 5 August 2026)."},{"key":"80_CR70","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1038\/s41587-022-01491-z","volume":"40","author":"E Rohner","year":"2022","unstructured":"Rohner, E., Yang, R., Foo, K. S., Goedel, A. & Chien, K. R. Unlocking the promise of mRNA therapeutics. Nat. Biotechnol. 40, 1586\u20131600 https:\/\/doi.org\/10.1038\/s41587-022-01491-z (2022).","journal-title":"Nat. Biotechnol."},{"key":"80_CR71","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.ymthe.2019.02.012","volume":"27","author":"PS Kowalski","year":"2019","unstructured":"Kowalski, P. S., Rudra, A., Miao, L. & Anderson, D. G. Delivering the messenger: advances in technologies for therapeutic mRNA delivery. Mol. Ther. 27, 710\u2013728 https:\/\/doi.org\/10.1016\/j.ymthe.2019.02.012 (2019).","journal-title":"Mol. Ther."},{"key":"80_CR72","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3390\/biomedicines13010097","volume":"13","author":"SK Niazi","year":"2025","unstructured":"Niazi, S. K. Affordable mRNA novel proteins, recombinant protein conversions, and biosimilars: advice to developers and regulatory agencies. Biomedicines 13, 97 https:\/\/doi.org\/10.3390\/biomedicines13010097 (2025).","journal-title":"Biomedicines"}],"container-title":["npj Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44386-026-00080-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44386-026-00080-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44386-026-00080-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:06:56Z","timestamp":1791824816000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44386-026-00080-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,12]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["80"],"URL":"https:\/\/doi.org\/10.1038\/s44386-026-00080-3","relation":{},"ISSN":["3005-1452"],"issn-type":[{"value":"3005-1452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,12]]},"assertion":[{"value":"11 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.K.N. is the chief executive officer of RNA Therapeutics, Abyolo BioRx, DEI Biopharma, and KaryoBio and holds equity interests in companies engaged in RNA and biological drug development. Some of these entities could benefit financially from the regulatory changes advocated in this article; the reader should weigh the arguments presented accordingly. S.K.N. has provided consulting and advisory services to regulatory authorities, including the United States Food and Drug Administration, the European Medicines Agency, and the Medicines and Healthcare products Regulatory Agency, which have taken the form of citizen petitions, responses to public consultations, and invited scientific presentations; however, none of these constitute a contractual or advisory relationship with those authorities.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"49"}}